MEDIMMUNE, ASTRAZENECA’S BIOLOGICS ARM, AND NGM BIOPHARMACEUTICALS ANNOUNCE AGREEMENT TO DISCOVER AND DEVELOP THERAPIES FOR DIABETES AND OBESITY

17 June 2013

AstraZeneca today announced that MedImmune, its global biologics research and
development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive
agreement to discover, develop and commercialise novel therapeutics from NGM’s
enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and
obesity.

EECs represent less than 1% of all gastrointestinal (GI) cells, but produce
virtually all of the known GI hormones, including GLP-1. EECs are an
underexplored source of novel hormones that could play a major role in the
positive and negative regulation of metabolism and glucose homeostasis. NGM has
established a proprietary platform capable of isolating and analysing EECs in
order to identify novel secreted peptide hormones that are potentially linked to
the profound metabolic effects of bariatric surgery and serve as potential
targets for the treatment of metabolic diseases.

MedImmune and NGM will jointly advance first-in-class peptide and antibody drug
candidates based on the discovered EEC hormones. MedImmune will have the option
to license in these EEC targets, and will be responsible for the global
development, manufacture and commercialisation of compounds resulting from the
collaboration.

“We believe that hormones found in the gastrointestinal tract can play an
important role in resolving diabetes after bariatric surgery. Through NGM’s
innovative research in metabolic disease, we believe our collaboration could
lead to potential innovative medicines for diabetes and obesity that will make a
difference in patients’ lives,” said Cristina Rondinone, Ph.D., Head of
Cardiovascular and Metabolic Disease Innovative Medicines Unit, MedImmune. “Our
partnership with NGM complements AstraZeneca’s existing small molecule and
biologics portfolio in cardiovascular and metabolic disease, one of our core
therapy areas.”

Under the terms of the agreement, MedImmune will make an upfront payment and
provide NGM research funding over the course of the collaboration. If certain
development, regulatory and commercial milestones are achieved, NGM will be
entitled to receive various payments, as well as royalties on worldwide product
sales.

“We are excited to enter into this strategic partnership with MedImmune as it
represents a unique opportunity to maximise the full complement of novel
hormones secreted by these EECs for drug discovery purposes,” said Jin-Long
Chen, Ph.D., founder, president and chief scientific officer of NGM. “Together,
NGM and MedImmune will build upon the culture of scientific excellence at both
organisations. With MedImmune’s deep biologics and development expertise, we are
confident that we will further enrich the pipeline of therapies for the
treatment of diabetes and obesity.”

– ENDS –

NOTES TO EDITORS

About NGM Biopharmaceuticals, Inc.
Founded in 2008, NGM is a privately-held drug discovery company in South San
Francisco, California committed to the identification and development of
transformational biologics for diabetes, obesity and other cardio-metabolic
diseases. The Company is focused on discovering the next generation of
therapeutics that will fundamentally change the treatment paradigm for the
growing population of diabetes and obesity patients worldwide. NGM has
established collaborations with Daiichi Sankyo, Janssen Pharmaceuticals and
JDRF. For more information, please visit the company’s website at
www.ngmbio.com.

About MedImmune
MedImmune is the worldwide biologics research and development arm of
AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses
on the discovery, development and commercialization of small molecule and
biologic prescription medicines.  MedImmune is pioneering innovative research
and exploring novel pathways across key therapeutic areas, including
respiratory, inflammation and autoimmunity; cardiovascular and metabolic
disease; oncology; neuroscience; and infection and vaccines. The MedImmune
headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global
R&D centers.  For more information, please visit www.medimmune.com.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler, +44 20 7604 8030 (UK/Global)
Vanessa Rhodes, +44 20 7604 8037 (UK/Global)
Ayesha Bharmal, +44 20 7604 8034 (UK/Global)
Tracy Rossin, +1 (301) 398-1468 (US/MedImmune)
Jacob Lund, +46 8 553 260 20 (Sweden)

Investor Enquiries
James Ward-Lilley, +44 20 7604 8122   mob: +44 7785 432613
Karl Hård, +44 20 7604 8123  mob: +44 7789 654364
Colleen Proctor, + 1 302 886 1842     mob: +1 302 357 4882
Ed Seage, + 1 302 886 4065     mob: +1 302 373 1361